Optimizing ADC value beyond approval through model-informed strategies
Originally aired: Thursday, April 2, 2026
As antibody–drug conjugates (ADCs) move from late-stage development into approval and commercialization, the role of modeling and simulation becomes increasingly strategic. Beyond supporting regulatory approval, model-informed approaches are essential for shaping labeling decisions, enabling global regulatory alignment, supporting expansion into…
